Lung ultrasounds can help clinicians identify patients with preeclampsia who have developed pulmonary edema.
Lung ultrasounds can detect both pulmonary edema and increased left ventricular end-diastolic pressure (LVEDP) in patients with severe preeclampsia, according to a study published in the journal Anesthesiology.
Researchers from Hopital Nord, in Marseille, France, undertook a prospective cohort study to assess the utility of using lung ultrasound for patients with severe preeclampsia. “Lung ultrasound is fast, safe, noninvasive, and easy to use,” lead author Marc Leone, MD, PhD, vice chair of the department of anesthesiology and critical care medicine at the hospital, said in a release. “We found it allowed us to quickly assess whether a woman with preeclampsia had pulmonary edema and confirm the severity of the condition.”
Twenty otherwise healthy adult patients with severe preeclampsia were enrolled in the study. They all underwent lung and cardiac ultrasounds before and after delivery. The researchers determined pulmonary edema using two scores: the B-pattern and the Echo Comet Score. Left ventricular end-diastolic pressures were assessed by transthoracic echocardiography.
The lung ultrasound images showed that five women (25 percent) had pulmonary edema before delivery and cardiac ultrasound found only four (20 percent) had the condition. The lung ultrasound also identified a patient with non-cardiac pulmonary edema, which had not been detected by the cardiac ultrasound.
“The striking finding of this preliminary study was that lung ultrasound detected B-pattern in 25 percent of patients with SP [severe preeclampsia],” wrote the authors. “The incidence was higher than that of clinical edema reported in the literature.”
The authors concluded that although further study is necessary, this preliminary study shows that ultrasound was an easy tool to help detect pulmonary edema and increased LVEDP in patients with severe preeclampsia.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.